Roche’s response to the COVID-19 pandemic

Coronavirus close up

COVID-19 pandemic

 

Timely availability and fast access to reliable, high quality tests are essential for healthcare systems.

Thomas Schinecker
Chief Executive Officer of Roche Diagnostics

Our commitment to help put a stop to the COVID-19 pandemic

 

Roche is deeply committed to supporting the global response to put an end to the COVID-19 pandemic. Around the world, we are working with urgency, passion and purpose each and every day to deliver high quality tests that are essential for healthcare systems and patients alike.

Detecting SARS-CoV-2 in currently infected patients with high sensitivity

Instrument Icon

Laboratory tests

Molecular test (PCR)

 

The cobas® SARS-CoV-2 Test is a real-time RT-PCR test intended for the qualitative detection of SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples from patients.

The cobas® SARS-CoV-2 & Influenza A/B Test is a real-time RT-PCR test intended for the qualitative detection and differentiation of SARS-CoV-2, Influenza A and Influenza B in nasal or nasopharyngeal swab samples collected from patients. 

Both tests can run on Roche’s fully automated cobas® 6800 and cobas® 8800 Systems under Emergency Use Authorization. Both tests are also available for countries accepting the CE-mark.

cobas® SARS-CoV-2 Test

cobas® SARS-CoV-2 & Influenza A/B Test

Elecsys® SARS-CoV-2 Antigen

 

The Elecsys® SARS-CoV-2 Antigen is an immunoassay for the qualitative detection of the SARS-CoV-2 nucleocapsid antigens.

Elecsys® SARS-CoV-2 Antigen

PoC tests icon

Point of Care tests

Molecular test (PCR)

 

The cobas® SARS-CoV-2 & Influenza A/B Assay is an automated multiplex real-time RT-PCR assay intended for the simultaneous rapid in vitro qualitative detection and differentiation of SARS-CoV-2., influenza A, and influenza B in nasopharyngeal and nasal swabs from patients suspected of respiratory viral infection.

The test is run on Roche's molecular point-of-care PCR testing solution, the cobas® Liat® System, under Emergency Use Authorization. It is also available for countries accepting the CE-mark.

cobas® SARS-CoV-2 & Influenza A/B Assay

Rapid antigen test

 

The SARS-CoV-2 Rapid Antigen Test is a reliable, rapid chromatopgraphic immunoassay for the qualitative detection of specific antigens of SARS-CoV-2 present in the human nasopharynx.

SARS-CoV-2 Rapid Antigen Test

Rapid Antigen Test Nasal

 

The SARS-CoV-2 Rapid Antigen Test Nasal is a reliable, rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen present in human nasal samples.

SARS-CoV-2 Rapid Antigen Test Nasal

Detecting a patient’s immune response to SARS CoV-2 with high specificity

Instrument Icon

Laboratory tests

Antibody tests

 

Elecsys® Anti-SARS-CoV-2 is an immunoassay for the in vitro qualitative detection of antibodies (including IgG) to SARS-CoV-2 in human serum and plasma. The test is intended as an aid in the determination of the immune reaction to SARS-CoV-2.

Elecsys® Anti-SARS-CoV-2 S is an immunoassay for the in vitro quantitative determination of antibodies (including IgG) to the SARS-CoV-2 spike (S) protein receptor binding domain (RBD) in human serum and plasma.

The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers.

Elecsys® Anti-SARS-CoV-2

Elecsys® Anti-SARS-CoV-2 S

PoC tests icon

Point of Care tests

Rapid Antibody tests

 

The SARS-CoV-2 Rapid Antibody Test is a reliable, rapid chromatographic immunoassay intended for qualitative detection of antibodies (IgM and IgG) to SARS-CoV-2 in human serum, plasma or whole blood.

The test is intended for the use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating prior infection.

SARS-CoV-2 Rapid Antibody Test

When to use which
SARS‑CoV‑2 diagnostic test1

 

Reliable diagnostic tests targeting patients that are currently infected by the virus, as well as those that have an immune response against the virus, are valuable. However, it is important to understand which tests are most suitable to use depending on their intended purpose.

*Whether immunity is gained by individuals who have been infected with SARS-CoV-2 is yet to be confirmed due to the novelty of the virus. Data presented here are based on current scientific understanding of the disease (April 2020)

icon of a person
Is my sickness COVID‑19?
icon of a person
How is my body's immune system reacting to the virus?

Our efforts to aid in epidemiological research

 

We continue our intensive research and development efforts to bring additional solutions to market to help study the spread of COVID-19 and emerging SARS-CoV-2 variants.

cobas® SARS-CoV-2 Variant Set 1

Virus illustration

Abbreviations

 

COVID-19: coronavirus disease 2019

RT-PCR: reverse transcription polymerase chain reaction

 
References
 
  1. European Commision (2020). Guidelines on COVID-19 in vitro diagnostic tests and their performance (published 15 April 2020). Available from https://ec.europa.eu/info/sites/info/files/testing_kits_communication.pdf [Accessed April 2020]